Sanofi India Limited and Sanofi Healthcare India Private Limited, collectively referred to as “Sanofi India”, have entered an exclusive partnership with Cipla Limited for the distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. Under this collaboration, Cipla will assume responsibility for distributing Sanofi India’s six CNS brands, including Frisium®, a prominent anti-epileptic medication.
While Sanofi India retains ownership and continues to import and manufacture its entire CNS product range across facilities in India and abroad, Cipla will utilize its extensive network and expertise in marketing and sales to enhance access to these treatments. Leveraging its wide-reaching presence and robust network of professionals, distributors, and institutions, Cipla aims to extend the availability of these therapies to patients nationwide.
Mr. Rodolfo Hrosz, Managing Director of Sanofi India Limited, expressed confidence in the partnership’s ability to broaden the reach of their portfolio to healthcare professionals and patients across India. Mr. Achin Gupta, Chief Executive Officer of One India Business at Cipla Limited, emphasized the joint commitment to improving patient access to high-quality treatments in the CNS domain. Recognizing the complexity of CNS disorders, both entities view this collaboration as a significant stride towards addressing unmet patient needs.
While focusing on expanding access to CNS therapies, Sanofi India remains dedicated to accelerating its innovation pipeline across various therapeutic areas, including Diabetes, Transplants, Rare Diseases, Consumer Healthcare, and Vaccines within the Indian market. This strategic alliance underscores the shared commitment of Sanofi India and Cipla to advance healthcare accessibility and quality across the nation.